We are live on ! Find out more
IMVT icon

Immunovant
IMVT

94 hedge funds and large institutions have $157M invested in Immunovant in 2022 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 31 increasing their positions, 31 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

299% more call options, than puts

Call options by funds: $2.51M | Put options by funds: $629K

0.46% more ownership

Funds ownership: 33.98% → 34.45% (+0.46%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 31

16% less funds holding

Funds holding: 112 → 94 (-18)

21% less capital invested

Capital invested by funds: $197M → $157M (-$40.5M)

54% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 26

Holders
94
Holders Change
-18
Holders Change %
-16.07%
% of All Funds
1.58%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
12
Increased
31
Reduced
31
Closed
26
Calls
$2.51M
Puts
$629K
Net Calls
+$1.88M
Net Calls Change
-$4.46M

Top Buyers

1
DTC
Deep Track Capital
Connecticut
+$9.63M
2
AGM
Alpine Global Management
New York
+$2.53M
3
BlackRock
BlackRock
New York
+$1.2M
4
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$1.1M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$1.01M

Top Sellers

1
OCA
Octagon Capital Advisors
New York
-$3.87M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$2.53M
3
MP
Mangrove Partners
Connecticut
-$2.03M
4
PAMP
Polar Asset Management Partners
Ontario, Canada
-$1.92M
5
Two Sigma Investments
Two Sigma Investments
New York
-$1.17M
Name Holding Trade Value Shares
Change 		Change in
Stake
Squarepoint
101
Squarepoint
New York
– -$154K -28,037 Closed
MIM
102
MetLife Investment Management
New Jersey
– -$139K -25,184 Closed
GCM
103
Graham Capital Management
Connecticut
– -$130K -23,655 Closed
VF
104
Virtu Financial
New York
– -$117K -21,250 Closed
Manulife (Manufacturers Life Insurance)
105
Manulife (Manufacturers Life Insurance)
Ontario, Canada
– -$112K -20,276 Closed
CC
106
Corton Capital
Ontario, Canada
– -$109K -19,854 Closed
JF
107
Jump Financial
Illinois
– -$103K -18,700 Closed
Balyasny Asset Management
108
Balyasny Asset Management
Illinois
– -$81K -14,616 Closed
EGM
109
Engineers Gate Manager
New York
– -$79K -14,300 Closed
CFD
110
Creative Financial Designs
Indiana
– -$77K -13,965 Closed
DU
111
Delphia (USA)
Ontario, Canada
– -$76K -13,713 Closed
PFS
112
Prospera Financial Services
Texas
– -$50K -9,135 Closed
MLICM
113
Metropolitan Life Insurance Company (MetLife)
New York
– -$15.2K -2,758 Closed
PHK
114
Point72 Hong Kong
Hong Kong
– -$13K -2,402 Closed
ACM
115
Aquatic Capital Management
Illinois
– -$8K -1,400 Closed
LC
116
Lindbrook Capital
California
– -$1K -232 -80%
HWMA
117
Heritage Wealth Management (Arizona)
Arizona
– -$1K -150 Closed
CAPTRUST Financial Advisors
118
CAPTRUST Financial Advisors
North Carolina
– -$1K -100 Closed
Simplex Trading
119
Simplex Trading
Illinois
– +$238 +55 New
Rockefeller Capital Management
120
Rockefeller Capital Management
New York
– +$968 +224 New
1 2 3 4
5

IMVT Hedge Fund Activity: Q2 2022 in Review

94 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Immunovant (IMVT) for Q2 2022, worth a combined $157M — down 21% from $197M a quarter earlier.

Sellers outnumbered buyers: 26 funds closed out of IMVT and 12 opened new positions — a net loss of 14 holders — while 31 trimmed existing stakes and 31 added.

The largest buyer was Deep Track Capital, adding an estimated $9.63M. The largest seller was Octagon Capital Advisors, cutting an estimated $3.87M.

  • 94 institutional investors held Immunovant (IMVT) as of Q2 2022, down from 112 in Q1 2022.
  • Funds reported $157M of Immunovant stock for Q2 2022, down 21% quarter-over-quarter.
  • 12 funds opened new Immunovant positions in Q2 2022 and 26 closed out, a net change of -14 holders.
  • The largest Immunovant buyer in Q2 2022 was Deep Track Capital, an estimated $9.63M added.
  • The largest Immunovant seller in Q2 2022 was Octagon Capital Advisors, an estimated $3.87M sold.

Based on aggregated 13F filings for Q2 2022.